Skip to main content
Top
Published in: Molecular Imaging and Biology 2/2011

01-04-2011 | Research Article

A Novel In Vitro Assay to Assess Phosphorylation of 3′-[18F]fluoro-3′-Deoxythymidine

Authors: Ning Guo, Jingping Xie, H. Charles Manning, Natasha G. Deane, M. Sib Ansari, Robert J. Coffey, John Gore, Ronald R. Price, Ronald M. Baldwin, J. Oliver McIntyre

Published in: Molecular Imaging and Biology | Issue 2/2011

Login to get access

Abstract

Purpose

3′-[18F]fluoro-3'-deoxythymidine ([18F]FLT) is phosphorylated by thymidine kinase 1 (TK-1), a cell cycle regulated enzyme. Appropriate use of [18F]FLT tracer requires validation of the TK-1 activity. Here, we report development of a novel phosphoryl-transfer assay to assess phosphorylation of [18F]FLT both in tumor cell lysates and tumor cells.

Procedures

The intrinsic F-18 radioactivity was used to quantify both substrate and phosphorylated products using a rapid thin layer chromatography method. Phosphorylation kinetics of [18F]FLT in SW480 and DiFi tumor cell lysates and cellular uptake were measured.

Results

The apparent Michaelis–Menten kinetic parameters for [18F]FLT are \( {K_{\rm{m}}} = {4}.{8}\pm 0.{3}\;{{\mu M}} \) and V max = 7.4 pmol min−1 per 1 × 106 cells with ∼2-fold higher TK-1 activity in DiFi versus SW480 lysates.

Conclusions

The apparent K m of [18F]FLT was comparable to the value reported with purified recombinant TK-1. The uptake of [18F]FLT by SW480 cells is inhibited by nitrobenzylthioinosine or dipyridamole indicating that uptake is mediated predominantly by the equilibrative nucleoside transporters in these tumor cells.
Literature
1.
go back to reference Kenny LM, Aboagye EO, Price PM (2004) Positron emission tomography imaging of cell proliferation in oncology. Clin Oncol 16:176–185CrossRef Kenny LM, Aboagye EO, Price PM (2004) Positron emission tomography imaging of cell proliferation in oncology. Clin Oncol 16:176–185CrossRef
2.
go back to reference Shield AF (2003) PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls. J Nucl Med 44:1432–1434 Shield AF (2003) PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls. J Nucl Med 44:1432–1434
3.
go back to reference Been LB, Suurmeijer AJH, Cobben DCP, Jager PL, Hoekstra HJ, Elsinga PH (2004) [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 31:1659–1672PubMedCrossRef Been LB, Suurmeijer AJH, Cobben DCP, Jager PL, Hoekstra HJ, Elsinga PH (2004) [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 31:1659–1672PubMedCrossRef
4.
go back to reference Giovanni L (2006) Imaging in cancer therapy and drug development. Eur J Nucl Med Mol Imaging 33:386–388CrossRef Giovanni L (2006) Imaging in cancer therapy and drug development. Eur J Nucl Med Mol Imaging 33:386–388CrossRef
5.
go back to reference Shield AF, Grierson JR, Dohmen BM, Machulla H-J, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med NY 4:1334–1336CrossRef Shield AF, Grierson JR, Dohmen BM, Machulla H-J, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med NY 4:1334–1336CrossRef
6.
go back to reference Reske SN, Deisenhofer S (2006) Is 3′-deoxy-3′-18F-fluorothymidine a better marker for tumour response than 18F-fluorodeoxyglucose? Eur J Nucl Med Mol Imaging 33(13):38–43PubMedCrossRef Reske SN, Deisenhofer S (2006) Is 3′-deoxy-3′-18F-fluorothymidine a better marker for tumour response than 18F-fluorodeoxyglucose? Eur J Nucl Med Mol Imaging 33(13):38–43PubMedCrossRef
7.
go back to reference Herrmann K, Wieder HA, AK AKB, Schoffel M, Krause B-J, Fend F, Schuster T, Buschenfelde CMZ, Wester H-J, Duyster J, Peschel C, Schwaiger M, Dechow T (2007) Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 13:3552–3558PubMedCrossRef Herrmann K, Wieder HA, AK AKB, Schoffel M, Krause B-J, Fend F, Schuster T, Buschenfelde CMZ, Wester H-J, Duyster J, Peschel C, Schwaiger M, Dechow T (2007) Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 13:3552–3558PubMedCrossRef
8.
go back to reference Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO (2007) Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34:1339–1347PubMedCrossRef Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO (2007) Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34:1339–1347PubMedCrossRef
9.
go back to reference Sohn HJ, Yang YJ, Ryu JS, Oh S, Im KC, HyukMoon D, Lee DH, Suh C, Lee JS, Kiml SW (2008) [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 14:7423–7429PubMedCrossRef Sohn HJ, Yang YJ, Ryu JS, Oh S, Im KC, HyukMoon D, Lee DH, Suh C, Lee JS, Kiml SW (2008) [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 14:7423–7429PubMedCrossRef
10.
go back to reference Krohn KA, Mankoff DA, Eary JF (2001) Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol 41:96S–103S Krohn KA, Mankoff DA, Eary JF (2001) Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol 41:96S–103S
11.
go back to reference Buck AK, Kratochwil C, Glatting G, Juweid M, Bommer M, Tepsic D, Vogg AT, Mattfeldt T, Neumaier B, Moller P, Reske SN (2007) Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. Eur J Nucl Med Mol Imaging 34:1775–1782PubMedCrossRef Buck AK, Kratochwil C, Glatting G, Juweid M, Bommer M, Tepsic D, Vogg AT, Mattfeldt T, Neumaier B, Moller P, Reske SN (2007) Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. Eur J Nucl Med Mol Imaging 34:1775–1782PubMedCrossRef
12.
go back to reference Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T (2007) Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25:4714–4721PubMedCrossRef Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T (2007) Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25:4714–4721PubMedCrossRef
13.
go back to reference Manning HC, Merchant NB, Foutch AC, Virostko JM, Wyatt SK, Shah C, McKinley ET, Xie J, Mutic NJ, Washington MK, LaFleur B, Tantawy MN, Peterson TE, Ansari MS, Baldwin RM, Rothenberg ML, Bornhop DJ, Gore JC, Coffey RJ (2008) Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res 14:7413–7422PubMedCrossRef Manning HC, Merchant NB, Foutch AC, Virostko JM, Wyatt SK, Shah C, McKinley ET, Xie J, Mutic NJ, Washington MK, LaFleur B, Tantawy MN, Peterson TE, Ansari MS, Baldwin RM, Rothenberg ML, Bornhop DJ, Gore JC, Coffey RJ (2008) Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res 14:7413–7422PubMedCrossRef
14.
go back to reference Ullrich RT, Zander T, Neumaier B, Koker M, Shimamura T, Waerzeggers Y, Borgman CL, Tawadros S, Li H, Sos ML, Backes H, Shapiro GI, Wolf J, Jacobs AH, Thomas RK, Winkeler A (2008) Early detection of erlotinib treatment response in NSCLC by 3′-deoxy-3′-[18F]-fluoro-l-thymidine ([18F]FLT) positron emission tomography (PET). PLoS ONE 3:e3908PubMedCrossRef Ullrich RT, Zander T, Neumaier B, Koker M, Shimamura T, Waerzeggers Y, Borgman CL, Tawadros S, Li H, Sos ML, Backes H, Shapiro GI, Wolf J, Jacobs AH, Thomas RK, Winkeler A (2008) Early detection of erlotinib treatment response in NSCLC by 3′-deoxy-3′-[18F]-fluoro-l-thymidine ([18F]FLT) positron emission tomography (PET). PLoS ONE 3:e3908PubMedCrossRef
15.
go back to reference Rasey JS, Grierson JR, Wiens LW, Kilb PD (2002) Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43:1210–1217PubMed Rasey JS, Grierson JR, Wiens LW, Kilb PD (2002) Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43:1210–1217PubMed
16.
go back to reference Seitz U, Wagner M, Neumaier B, Wawra E, Glatting G, Leder G, Schmid RM, Reske SN (2002) Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3′-[(18)F]fluoro-3′-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging 29:1174–1181PubMedCrossRef Seitz U, Wagner M, Neumaier B, Wawra E, Glatting G, Leder G, Schmid RM, Reske SN (2002) Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3′-[(18)F]fluoro-3′-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging 29:1174–1181PubMedCrossRef
17.
go back to reference Barthel H, Perumal M, Latigo J, He Q, Brady F, Luthra SK, Price PM, Aboagye EO (2005) The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 32:257–263PubMedCrossRef Barthel H, Perumal M, Latigo J, He Q, Brady F, Luthra SK, Price PM, Aboagye EO (2005) The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 32:257–263PubMedCrossRef
18.
go back to reference Al-Madhoun AS, Johnsamuel J, Barth RF, Tjarks W, Eriksson S (2004) Evaluation of human thymidine kinase 1 substrates as new candidates for boron neutron capture therapy. Cancer Res 64:6280–6286PubMedCrossRef Al-Madhoun AS, Johnsamuel J, Barth RF, Tjarks W, Eriksson S (2004) Evaluation of human thymidine kinase 1 substrates as new candidates for boron neutron capture therapy. Cancer Res 64:6280–6286PubMedCrossRef
19.
go back to reference Lunato AJ, Wang J, Woollard JE, Anisuzzaman AK, Ji W, Rong FG, Ikeda S, Soloway AH, Eriksson S, Ives DH, Blue TE, Tjarks W (1999) Synthesis of 5-(carboranylalkylmercapto)-2′-deoxyuridines and 3-(carboranylalkyl)thymidines and their evaluation as substrates for human thymidine kinases 1 and 2. J Med Chem 42:3378–3389PubMedCrossRef Lunato AJ, Wang J, Woollard JE, Anisuzzaman AK, Ji W, Rong FG, Ikeda S, Soloway AH, Eriksson S, Ives DH, Blue TE, Tjarks W (1999) Synthesis of 5-(carboranylalkylmercapto)-2′-deoxyuridines and 3-(carboranylalkyl)thymidines and their evaluation as substrates for human thymidine kinases 1 and 2. J Med Chem 42:3378–3389PubMedCrossRef
20.
go back to reference Toyohara J, Hayashi A, Gogami A, Hamada M, Hamashima Y, Katoh T, Node M, Fujibayashi Y (2006) Alkyl-fluorinated thymidine derivatives for imaging cell proliferation I. The in vitro evaluation of some alkyl-fluorinated thymidine deriv. Nucl Med Biol 33:751–764PubMedCrossRef Toyohara J, Hayashi A, Gogami A, Hamada M, Hamashima Y, Katoh T, Node M, Fujibayashi Y (2006) Alkyl-fluorinated thymidine derivatives for imaging cell proliferation I. The in vitro evaluation of some alkyl-fluorinated thymidine deriv. Nucl Med Biol 33:751–764PubMedCrossRef
21.
go back to reference Byun Y, Yan J, Al-Madhoun AS, Johnsamuel J, Yang W, Barth RF, Eriksson S, Tjarks W (2005) Synthesis and biological evaluation of neutral and zwitterionic 3-carboranyl thymidine analogues for boron neutron capture therapy. J Med Chem 48:1188–1198PubMedCrossRef Byun Y, Yan J, Al-Madhoun AS, Johnsamuel J, Yang W, Barth RF, Eriksson S, Tjarks W (2005) Synthesis and biological evaluation of neutral and zwitterionic 3-carboranyl thymidine analogues for boron neutron capture therapy. J Med Chem 48:1188–1198PubMedCrossRef
22.
go back to reference Johnsamuel J, Lakhi N, Al-Madhoun AS, Byun Y, Yan J, Eriksson S, Tjarksa W (2004) Synthesis of ethyleneoxide modified 3-carboranyl thymidine analogues and evaluation of their biochemical, physicochemical, and structural properties. Bioorg Med Chem 12:4769–4788PubMedCrossRef Johnsamuel J, Lakhi N, Al-Madhoun AS, Byun Y, Yan J, Eriksson S, Tjarksa W (2004) Synthesis of ethyleneoxide modified 3-carboranyl thymidine analogues and evaluation of their biochemical, physicochemical, and structural properties. Bioorg Med Chem 12:4769–4788PubMedCrossRef
23.
go back to reference Byun Y, Yan J, Al-Madhoun AS, Johnsamuel J, Yang W, Barth RF, Eriksson S, Tjarksa W (2004) The synthesis and biochemical evaluation of thymidine analogues substituted with nido carborane at the N-3 position. Appl Radiat Isot 61:1125–1130PubMedCrossRef Byun Y, Yan J, Al-Madhoun AS, Johnsamuel J, Yang W, Barth RF, Eriksson S, Tjarksa W (2004) The synthesis and biochemical evaluation of thymidine analogues substituted with nido carborane at the N-3 position. Appl Radiat Isot 61:1125–1130PubMedCrossRef
24.
go back to reference Zhang F, Shao X, Li H, Robison JG, Murray BK, O'Neill KL (2001) A monoclonal antibody specific for human thymidine kinase 1. Hybridoma 20:25–34PubMedCrossRef Zhang F, Shao X, Li H, Robison JG, Murray BK, O'Neill KL (2001) A monoclonal antibody specific for human thymidine kinase 1. Hybridoma 20:25–34PubMedCrossRef
25.
go back to reference Baldwin SA, Mackey JR, Cass CE, Young JD (1999) Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today 5:216–224PubMedCrossRef Baldwin SA, Mackey JR, Cass CE, Young JD (1999) Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today 5:216–224PubMedCrossRef
26.
go back to reference Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, Cass CE (2003) Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22:7524–7536PubMedCrossRef Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, Cass CE (2003) Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22:7524–7536PubMedCrossRef
27.
go back to reference King AE, Ackley MA, Cass CE, Young JD, Baldwin SA (2006) Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci 27:416–425PubMedCrossRef King AE, Ackley MA, Cass CE, Young JD, Baldwin SA (2006) Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci 27:416–425PubMedCrossRef
28.
go back to reference Zhang J, Visser F, King KM, Baldwin SA, Young JD, Cass CE (2007) The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev 26:85–110PubMedCrossRef Zhang J, Visser F, King KM, Baldwin SA, Young JD, Cass CE (2007) The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev 26:85–110PubMedCrossRef
29.
go back to reference Perumal M, Pillai RG, Barthel H, Leyton J, Latigo JR, Forster M, Mitchell F, Jackman AL, Aboagye EO (2006) Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res 66:8558–8564PubMedCrossRef Perumal M, Pillai RG, Barthel H, Leyton J, Latigo JR, Forster M, Mitchell F, Jackman AL, Aboagye EO (2006) Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res 66:8558–8564PubMedCrossRef
30.
go back to reference Machulla HJ, Blocher A, Kuntzsch M, Piert M, Wei R, Grierson JR (2000) Simplified labeling approach for synthesizing 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT). J Radioanal Nucl Chem 243:843–846CrossRef Machulla HJ, Blocher A, Kuntzsch M, Piert M, Wei R, Grierson JR (2000) Simplified labeling approach for synthesizing 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT). J Radioanal Nucl Chem 243:843–846CrossRef
31.
go back to reference Reischl G, Blocher A, Wei R, Ehrlichmann W, Kuntzsch M, Solbach C, Dohmen BM, Machulla H-J (2006) Simplified, automated synthesis of 3′-[18F]fluoro-3′-deoxythymidine ([18F]FLT) and simple method for metabolite analysis in plasma. Radiochim Acta 94:447–451CrossRef Reischl G, Blocher A, Wei R, Ehrlichmann W, Kuntzsch M, Solbach C, Dohmen BM, Machulla H-J (2006) Simplified, automated synthesis of 3′-[18F]fluoro-3′-deoxythymidine ([18F]FLT) and simple method for metabolite analysis in plasma. Radiochim Acta 94:447–451CrossRef
32.
go back to reference Manning HC, Merchant NB, Foutch AC, Virostko JM, Wyath SK, Shah C, McKinly ET, Xie J, Mutic NJ, Washington MK, LaFleur B, Tantawy MN, Peterson TE, Ansari MS, Baldwin RM, Rothenberg ML, Bornhop DJ, Gore JC, Coffey RJ (2008) Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin. Cancer Res 14, 7413–7422 Manning HC, Merchant NB, Foutch AC, Virostko JM, Wyath SK, Shah C, McKinly ET, Xie J, Mutic NJ, Washington MK, LaFleur B, Tantawy MN, Peterson TE, Ansari MS, Baldwin RM, Rothenberg ML, Bornhop DJ, Gore JC, Coffey RJ (2008) Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin. Cancer Res 14, 7413–7422
33.
go back to reference Olive M, Untawale S, Coffey RJ, Siciliano MJ, Wildrick DM, Fritsche H (1993) Characterization of the DiFi rectal carcinoma cell line derived from a familial adenomatous polyposis patient. In Vitro Cell Dev Biol 29A:239–248PubMedCrossRef Olive M, Untawale S, Coffey RJ, Siciliano MJ, Wildrick DM, Fritsche H (1993) Characterization of the DiFi rectal carcinoma cell line derived from a familial adenomatous polyposis patient. In Vitro Cell Dev Biol 29A:239–248PubMedCrossRef
34.
go back to reference He Q, Skog S, Welander I, Tribukait B (2002) X-irradiation effects on thymidine kinase (TK): II. The significance of deoxythymidine triphosphate for inhibition of TK1 activity. Cell Prolif 35:83–92PubMedCrossRef He Q, Skog S, Welander I, Tribukait B (2002) X-irradiation effects on thymidine kinase (TK): II. The significance of deoxythymidine triphosphate for inhibition of TK1 activity. Cell Prolif 35:83–92PubMedCrossRef
35.
go back to reference Buursma A, van Dillen I, van Waarde A, Vaalburg W, Hospers G, Mulder N, de Vries E (2004) Monitoring HSVtk suicide gene therapy: the role of [(18)F]FHPG membrane transport. Br J Cancer 91:2079–2085PubMedCrossRef Buursma A, van Dillen I, van Waarde A, Vaalburg W, Hospers G, Mulder N, de Vries E (2004) Monitoring HSVtk suicide gene therapy: the role of [(18)F]FHPG membrane transport. Br J Cancer 91:2079–2085PubMedCrossRef
36.
go back to reference Munch-Petersen B, Cloos L, Jensen H, Tyrsted G (1995) Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 35:69–89PubMedCrossRef Munch-Petersen B, Cloos L, Jensen H, Tyrsted G (1995) Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 35:69–89PubMedCrossRef
37.
go back to reference Grierson JR, Schwartz JL, Muzi M, Jordan R, Krohn KA (2004) Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: validations for postron emission tomography. Nucl Med Biol 31:829–837PubMedCrossRef Grierson JR, Schwartz JL, Muzi M, Jordan R, Krohn KA (2004) Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: validations for postron emission tomography. Nucl Med Biol 31:829–837PubMedCrossRef
38.
go back to reference Munch-Petersen B, Cloosll L, Tyrstedn G, Eriksson S (1991) Diverging substrate specificity of pure human thymidine kinase 1 and 2 aginst antiviral dideoxynucleosides. J Biol Chem 266:9032–9038PubMed Munch-Petersen B, Cloosll L, Tyrstedn G, Eriksson S (1991) Diverging substrate specificity of pure human thymidine kinase 1 and 2 aginst antiviral dideoxynucleosides. J Biol Chem 266:9032–9038PubMed
39.
go back to reference Schaer J, Maurer U, Schindler R (1978) Determination of thymidine in serum used for cell culture media. Exp Cell Biol 46:1–10PubMed Schaer J, Maurer U, Schindler R (1978) Determination of thymidine in serum used for cell culture media. Exp Cell Biol 46:1–10PubMed
40.
go back to reference Gentry GA, Morse PAJ, Ives DH, Gebert R, Potter VR (1965) Pyrimidine metabolism in tissue culture cells derived from rat hepatomas II. Thymidine uptake in suspension cultures derived from the novikoff hepatoma. Cancer Res 25:509–516PubMed Gentry GA, Morse PAJ, Ives DH, Gebert R, Potter VR (1965) Pyrimidine metabolism in tissue culture cells derived from rat hepatomas II. Thymidine uptake in suspension cultures derived from the novikoff hepatoma. Cancer Res 25:509–516PubMed
41.
go back to reference Kong X-B, Zhu Q-Y, Vidal PM, Watanabe KA, Polsky B, Amstrong D, Ostrander M, JR SAL, Muchmore E, Chou T-C (1992) Comparisons of anti-human Immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′ deoxythymidine. Antimicrob Agents Chemother 35:808–818 Kong X-B, Zhu Q-Y, Vidal PM, Watanabe KA, Polsky B, Amstrong D, Ostrander M, JR SAL, Muchmore E, Chou T-C (1992) Comparisons of anti-human Immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′ deoxythymidine. Antimicrob Agents Chemother 35:808–818
42.
go back to reference Alauddin MM, Conti PS, Fissekis JD (2003) A general synthesis of 2′-deoxy-2′-[18F]fluoro-1-β-d-arabinofuranosyluracil and its 5-substituted nucleosides. J Label Compd Radiopharm 46:285–289CrossRef Alauddin MM, Conti PS, Fissekis JD (2003) A general synthesis of 2′-deoxy-2′-[18F]fluoro-1-β-d-arabinofuranosyluracil and its 5-substituted nucleosides. J Label Compd Radiopharm 46:285–289CrossRef
Metadata
Title
A Novel In Vitro Assay to Assess Phosphorylation of 3′-[18F]fluoro-3′-Deoxythymidine
Authors
Ning Guo
Jingping Xie
H. Charles Manning
Natasha G. Deane
M. Sib Ansari
Robert J. Coffey
John Gore
Ronald R. Price
Ronald M. Baldwin
J. Oliver McIntyre
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
Molecular Imaging and Biology / Issue 2/2011
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-010-0351-8

Other articles of this Issue 2/2011

Molecular Imaging and Biology 2/2011 Go to the issue